Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec;36(6):549-552.
doi: 10.1016/j.jpag.2023.06.005. Epub 2023 Jun 22.

A Pilot Study of Adolescent and Young Adult Experience with Subcutaneous Depot Medroxyprogesterone Acetate

Affiliations

A Pilot Study of Adolescent and Young Adult Experience with Subcutaneous Depot Medroxyprogesterone Acetate

Hunter J Wernick et al. J Pediatr Adolesc Gynecol. 2023 Dec.

Abstract

Study objective: To describe satisfaction with and preference for subcutaneous depot medroxyprogesterone acetate (DMPA-SC), along with adherence and feasibility, in adolescents and young adults (AYAs) METHODS: Survey of a sample of AYA patients who received DMPA-SC prescription and injection RESULTS: Of 108 eligible patients, 34 completed the survey, and 29 respondents received at least 1 DMPA-SC injection. The mean age was 16.9 years. Seventy-nine point three percent used it for gynecologic reasons, 27.6% for gender dysphoria, and 20.7% for contraception (multiple responses allowed); 93.1% were satisfied with DMPA-SC; 78.6% gave DMPA-SC on time; 88.9% reported that giving the injection was easy; 89.7% reported no problems with administration; 89.3% reported no problems obtaining DMPA-SC; and 76.9% plan to continue using DMPA-SC.

Conclusion: In this small sample of patients within a children's hospital, the overall experience with DMPA-SC was favorable. Clinicians caring for adolescents should consider including DMPA-SC in counseling when depot medroxyprogesterone acetate (DMPA) is indicated.

Keywords: Adolescent; Contraceptive agents (female); Feasibility studies; Female; Humans; Injections (subcutaneous); Medroxyprogesterone acetate; Patient satisfaction; Young adult.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest HJW, EW, KJ, KS, OV, and AEB have no potential conflicts to disclose. EB received research funding from Merck and receives research funding from Organon, has been a consultant for Merck, and was a Nexplanon Clinical Trainer for Merck.

Substances

LinkOut - more resources